Roche Holding AG - ADR
RHHBY
Get informed when a big investor buys or sells
+ FollowEarnings Call Q2 2024
July 25, 2024 - AI Summary
Exclusive for Stockcircle Pro members
Sign up
Current Fair Value
39.1% upsideUndervalued by 39.1% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $327.35 Billion |
|---|---|
| Enterprise Value | $354.67 Billion |
| Dividend Yield | $1.55 (3.06%) |
| Earnings per Share | $2.02 |
| Beta | 0.33 |
| Outstanding Shares | 6,422,535,208 |
Return
| Return on Equity | 62.57% |
|---|---|
| Return on Assets | 21.00% |
| Return on Invested Capital | 40.95% |
Valuation & Multiples
| P/E Ratio | 19.76 |
|---|---|
| PEG | 11.55 |
| Price to Sales | 2.59 |
| Price to Book Ratio | 9.83 |
| Enterprise Value to Revenue | 2.88 |
| Enterprise Value to EBIT | 11.91 |
| Enterprise Value to Net Income | 16 |
| Total Debt to Enterprise | 0.09 |
| Debt to Equity | 0.97 |
Revenue Sources
No data
Insider Trades
Last Earnings Call
Next Earnings Call
Institutional Put/Call Ratio
Market sentiment based on institutional option activity.
| Put/Call Ratio | 0.00000% |
|---|---|
| Total Calls | - |
| Total Puts | - |
Institutional Ownership
Holdings and activity of institutional investors.
| Ownership % | 0.09%▼ 0.01% |
|---|---|
| Total Invested | $276.65M▼ 10.50% |
| Investors Holding | 67▼ 5.00% |
ESG Score
No data
About Roche Holding AG
CEO: Severin Schwan Roche Holding AG operates as a research healthcare company. It operates through the following segments: Diagnostics and Pharmaceuticals. The Pharmaceutical segment refers to development of medicines in the field of oncology, immunology, ...
Relevant Senate Committees
This committee controls taxation, trade, and entitlement spending (e.g., Medicare, Medicaid). Its decisions on corporate tax policy directly affect Roche's profitability, and its influence on drug pricing within federal health programs significantly impacts Roche's revenue streams.
This committee allocates federal discretionary spending, directly influencing the budgets of agencies vital to Roche, such as the NIH (for research funding) and the FDA (for regulatory oversight capacity), as well as federal healthcare programs that purchase Roche's products.
This committee directly regulates the FDA and NIH, which are critical for Roche. FDA approval is mandatory for all pharmaceutical and diagnostic products, and NIH funding influences the scientific research landscape that Roche operates within and draws from.